Clinical trial
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
NCT00004929 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004929 |
|---|---|
| Title | Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer |
| Official title | Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Examining the Immunogenicity of Glycosylated MUC-2-KLH Peptide Conjugate Vaccine |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | MUC-2-KLH vaccine, QS21 |
| Enrollment | 15 |
| Start date | Sep 1, 1999 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jun 18, 2004 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: